Results 81 to 90 of about 3,601 (193)
Evaluating 5-nitrofurans as trypanocidal agents [PDF]
, 2013 The nitroheterocycle nifurtimox, as part of a nifurtimox-eflornithine combination therapy, represents one of a limited number of treatments targeting Trypanosoma brucei, the causative agent of human African trypanosomiasis.
Alvarez, G +6 more
core +1 more source
Dermatological care of gender‐diverse patients in Australia
Australasian Journal of Dermatology, Volume 65, Issue 8, Page 601-609, December 2024.Abstract In recent years, there has been an increasing recognition of the unique healthcare needs of gender‐diverse patients in Australia. With the continuous growth of referrals to gender health services, there is an increased demand for specialised dermatological care.
Roy Kingsley Wong +2 more
wiley +1 more source
Ornithine uptake and the modulation of drug sensitivity in Trypanosoma brucei [PDF]
, 2017 Trypanosoma brucei, protozoan parasites that cause human African trypanosomiasis (HAT), depend on ornithine uptake and metabolism by ornithine decarboxylase (ODC) for survival. Indeed, ODC is the target of the WHO "essential medicine" eflornithine, which
Alsford, Sam +5 more
core +4 more sources
Metabolomics and lipidomics reveal perturbation of sphingolipid metabolism by a novel anti-trypanosomal 3-(oxazolo[4,5-b]pyridine-2-yl)anilide [PDF]
, 2016 Introduction: Trypanosoma brucei is the causative agent of human African trypanosomiasis, which is responsible for thousands of deaths every year. Current therapies are limited and there is an urgent need to develop new drugs.
Avery, Vicky M. +11 more
core +2 more sources
Hydrazinated geraniol derivatives as potential broad‐spectrum antiprotozoal agents
Archiv der Pharmazie, Volume 357, Issue 10, October 2024.Hydrazinated geraniol derivatives were synthesised and tested in vitro against different parasitic protozoans of clinical relevance, including Trypanosoma brucei brucei, Trypanosoma brucei rhodesiense, Trypanosoma cruzi and Leishmania infantum. Compounds 6, 8, 13, 14 and 15 demonstrated low micromolar activity against the different parasites.
Joelien Jooste +4 more
wiley +1 more source
Revue d’Elevage et de Médecine Vétérinaire des Pays Tropicaux, 1997 De la difluorométhylornithine (DFMO, eflornithine) a été donnée par voie intraveineuse (lV) à des chiens infectés expérimentalement par Trypanosoma brucei.
B.M. Anene, S.M. Anika, C.C. Chukwu
doaj +1 more source
Case of Nigeria-Acquired Human African Trypanosomiasis in United Kingdom, 2016. [PDF]
, 2017 Human African trypanosomiasis has not been reported in Nigeria since 2012. Nevertheless, limitations of current surveillance programs mean that undetected infections may persist.
Brooks, Tim +6 more
core +3 more sources
ChemistrySelect, Volume 9, Issue 35, September 18, 2024.A series of trifluoromethylthiolated cinnamate derivatives have demonstrated promising potential applications as topical antidermatophytic agents. In particular, two derivatives have a lower propensity for cytotoxicity at low concentrations and a low irritant potential profile, even at concentrations 6–30 times higher than the Minimum Inhibitory ...
Luana Candice Genz Bazana +8 more
wiley +1 more source
Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma? [PDF]
, 2011 Purpose Neuroblastoma is the most common extracranial solid tumour in childhood. It accounts for 15% of all paediatric oncology deaths. In the last few decades, improvement in treatment outcome for high-risk patients has not occurred, with an overall ...
Francesco Bellanti +2 more
core +2 more sources
Medicinal Research Reviews, Volume 44, Issue 5, Page 2078-2111, September 2024.Abstract As the world population ages, there will be an increasing need for effective therapies for aging‐associated neurodegenerative disorders, which remain untreatable. Dementia due to Alzheimer's disease (AD) is one of the leading neurological diseases in the aging population.
Viswanath Das +6 more
wiley +1 more source